Radiotherapy Induced Oral Mucositis Treatment Market
Number of pages: 100 | Report Format: PDF | Published date: April 25, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 2.73 billion |
|
Revenue Forecast in 2031 |
US$ 4.18 billion |
|
CAGR |
4.87% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global radiotherapy induced oral mucositis treatment market was valued at US$ 2.73 billion in 2022 and is expected to register a revenue CAGR of 4.87% to reach US$ 4.18 billion by 2031.
Radiotherapy Induced Oral Mucositis Treatment Market Fundamentals
Radiotherapy-induced oral mucositis is a frequent adverse effect of cancer treatment radiation therapy. It refers to inflammation and damage to the oral mucosa, which may result in painful ulcers; difficulties in eating, speaking, and swallowing; and reduced quality of life in cancer patients. Radiotherapy-induced oral mucositis management is a crucial component of cancer care, and numerous therapeutic methods have been developed to reduce symptoms and enhance patient outcomes. These therapies attempt to reduce the intensity and duration of oral mucositis. They may include pharmaceutical interventions like analgesics, anti-inflammatory medications, and mouthwashes and supportive care measures like adequate oral hygiene, diet, and pain management.
In recent years, there has been a surge of interest in the development of novel therapies for radiotherapy-induced oral mucositis. New agents are currently in the pipeline for the prevention and/or management of radiation-induced oral mucositis. For instance, Benzydamine, a non-steroidal anti-inflammatory agent that inhibits TNF-a, has been shown to be effective in controlling oral mucositis and pain due to radiotherapy. Other potential agents being investigated include palifermin, a recombinant human keratinocyte growth factor that stimulates the growth of cells lining the mouth and gut and has shown promise in preventing severe oral mucositis in cancer patients undergoing high-dose chemotherapy.
Market players active in the research and marketing therapies for radiotherapy-induced oral mucositis are employing various techniques to address the rising need for effective interventions. A few strategies being adopted are research on combination medicines, individualized treatment methods, research & development to uncover novel therapeutic targets, and innovative treatment modalities. These initiatives seek to deliver more tailored and effective therapies while reducing the risk of side effects.
[10]
Radiotherapy Induced Oral Mucositis Treatment Market Dynamics
The increased global prevalence of cancer is boosting demand for radiation, a frequent treatment technique for numerous forms of cancer. As more patients prefer radiation therapy, the prevalence of radiotherapy-induced oral mucositis rises. According to the National Center for Biotechnology Information, radiation-induced oral mucositis affects up to 80% of patients with head and neck cancer who have been irradiated. It can affect 100% of patients with altered fractionation head and neck cancer. This has resulted in an increased demand for effective therapies to manage and alleviate the symptoms of oral mucositis, boosting the demand for radiotherapy-induced oral mucositis treatment.
Market players are increasingly launching new drugs for radiotherapy induced oral mucositis. This trend is driven by the growing demand for effective treatment options with minimal side effects. For instance, according to a news statement from Galera Therapeutics, the Food and Drug Administration (FDA) has approved and given priority review to a new medication application for avasopasem manganese (GC4419) for radiotherapy-induced severe oral mucositis in patients with head and neck cancer in Feb 2023. It is a significant development in the field of cancer treatment, as it addresses an unmet medical need and can potentially improve patient outcomes.
Moreover, ongoing research & developments have concluded many new therapeutic options and alternatives to radiotherapy induced oral mucositis. For instance, research conducted by Biomedical Research Center in Zhejiang, China, in 2021 concluded that Quercetin prevents radiation induced oral mucositis. This is a promising discovery as quercetin is a naturally occurring flavonoid in many fruits and vegetables, offering it a safe and accessible alternative to standard therapies. More research is needed to evaluate the efficacy of Quercetin in preventing oral mucositis in humans.
Despite the promising potential of radiotherapy induced oral mucositis treatments, the high cost and limited accessibility of these therapies remain a significant restraining factor for the market growth. However, ongoing research & development activities to develop cost-effective and easily accessible treatments are expected to drive market revenue growth during the forecast period.
Radiotherapy Induced Oral Mucositis Treatment Market Ecosystem
The global radiotherapy induced oral mucositis treatment market is analyzed from three perspectives: drug class, distribution channel, and region.
Radiotherapy Induced Oral Mucositis Treatment Market by Drug Class
[23]
Based on the drug class, the global radiotherapy induced oral mucositis treatment market is segmented into anti-inflammatory, antibiotics, anti-neoplastic, and antifungal.
In 2022, the anti-inflammatory segment dominated the global radiotherapy induced oral mucositis treatment market in terms of revenue share. This can be attributed to the high efficacy of anti-inflammatory drugs in reducing inflammation and pain associated with oral mucositis. These drugs can also help prevent the development of severe oral mucositis, improving the quality of life for cancer patients. Moreover, anti-inflammatory drugs for mucositis treatment are available in many forms, including topical solutions, mouthwashes, sprays, and gels, making it a convenient option for patients.
Radiotherapy Induced Oral Mucositis Treatment Market by Distribution Channel
Based on the distribution channel, the global radiotherapy induced oral mucositis treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
In 2022, the hospital pharmacies segment accounted for the majority of market revenue share in the global radiotherapy induced oral mucositis treatment market. This can be attributed to the fact that hospital pharmacies are the primary source of medication for patients undergoing radiotherapy treatment. Additionally, hospital pharmacies have well-established relationships with healthcare providers and are often preferred due to their ability to provide specialized care and support. Furthermore, hospital pharmacies have access to advanced technology and equipment necessary for preparing and administering complex radiotherapy medications, which community pharmacies may still need to do. This makes hospital pharmacies the go-to for patients requiring specialized medication management during radiotherapy treatment.
The retail pharmacies segment is expected to show a high revenue CAGR during the forecast period. This revenue growth is attributed to the increasing demand for over-the-counter drugs and the rising prevalence of chronic diseases. Additionally, the expansion of retail pharmacy chains in emerging economies is also expected to contribute to the revenue growth of this segment. Moreover, the availability of a wide range of OTC drugs without a prescription is also driving the revenue growth of the over-the-counter drugs market. Furthermore, the increasing adoption of e-commerce platforms for purchasing medicines will provide lucrative opportunities for the online pharmacies market during the forecast period.
Radiotherapy Induced Oral Mucositis Treatment Market by Region
Based on the region, the global radiotherapy induced oral mucositis treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for the highest revenue share in 2022. This growth is attributed to the increasing prevalence of cancer and the rising adoption of advanced treatment options such as radiotherapy in the region. Additionally, the well-established healthcare infrastructure, favorable reimbursement policies, prominent players in the region, and growing government initiatives for cancer treatment contribute to North America's market revenue growth. The increasing awareness among the population about early cancer diagnosis and treatment is also driving market revenue growth. Moreover, the availability of skilled healthcare professionals and the presence of leading market players in the region are expected to boost market revenue growth.
The European radiotherapy induced oral mucositis treatment market is characterized by established players and new entrants competing based on their product offerings and pricing strategies. The increasing prevalence of cancer and the growing demand for advanced radiotherapy treatments are expected to drive market revenue growth during the forecast period.
The Asia Pacific radiotherapy induced oral mucositis treatment market is expected to show higher revenue growth due to the increasing prevalence of cancer in the region and the rising adoption of advanced radiotherapy techniques for cancer treatment, which often result in oral mucositis as a side effect. Additionally, the growing awareness about the benefits of early diagnosis and treatment of oral mucositis is expected to drive market revenue growth.
Radiotherapy Induced Oral Mucositis Treatment Market Competitive Landscape
The competitive landscape of the radiotherapy induced oral mucositis treatment market is characterized by several established players and emerging companies. These companies are focusing on research and development activities to introduce innovative products to the market. The increasing prevalence of cancer and the rising demand for effective treatment options are expected to drive market revenue growth during the forecast period. Additionally, favorable government initiatives and increasing investments in healthcare infrastructure are expected to boost market revenue growth further.
The prominent companies operating in the global radiotherapy induced oral mucositis treatment market are,
Radiotherapy Induced Oral Mucositis Treatment Market Recent Developments
The radiotherapy induced oral mucositis treatment market is expected to experience significant growth due to the increasing prevalence of cancer and the rising demand for effective treatment options. Moreover, technological advancements in radiotherapy techniques and the development of novel therapies are also expected to contribute to market revenue growth.
According to the deep-dive market assessment study by Growth Plus Reports, the global radiotherapy induced oral mucositis treatment market was valued at US$ 2.73 billion in 2022.
Some major strategies key market players adopt in the radiotherapy induced oral mucositis treatment market include mergers and acquisitions, partnerships and collaborations, and product launches. These strategies help companies to expand their product portfolio, strengthen their market position, and enhance their geographic presence.
Based on drug class, the global radiotherapy induced oral mucositis treatment market is segmented into anti-inflammatory, antibiotics, anti-neoplastic, and antifungal. In 2022, the anti-inflammatory segment dominated the global radiotherapy induced oral mucositis treatment market in terms of revenue share.
The global radiotherapy induced oral mucositis treatment market is expected to register a revenue CAGR of 4.87% to reach US$ 4.18 billion by 2031.
*Insights on financial performance are subject to the availability of information in the public domain